Wisconsin 2023-2024 Regular Session

Wisconsin Senate Bill SB727 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	LRB-5129/1
2	2	JAM:cjs&emw
3	3	2023 - 2024 LEGISLATURE
4	4	2023 SENATE BILL 727
5	5	November 21, 2023 - Introduced by Senators JAMES, HESSELBEIN, AGARD, LARSON,
6	6	ROYS and SPREITZER, cosponsored by Representatives G USTAFSON, C.
7	7	ANDERSON, J. ANDERSON, BARE, BROOKS, CONSIDINE, EDMING, EMERSON,
8	8	JACOBSON, JOERS, MURPHY, OHNSTAD, ORTIZ-VELEZ, RATCLIFF, SAPIK,
9	9	SHANKLAND and SINICKI. Referred to Committee on Universities and Revenue.
10	10	AN ACT to create 20.285 (1) (qh), 20.285 (1) (qi), 25.14 (1) (a) 14m., 25.17 (1) (jw),
11	11	25.51 and 36.25 (16) of the statutes; relating to: creating a medicinal
12	12	psilocybin treatment fund and a pilot program to study the effects of medicinal
13	13	psilocybin treatment on patients with post-traumatic stress syndrome at the
14	14	University of Wisconsin-Madison and making an appropriation.
15	15	Analysis by the Legislative Reference Bureau
16	16	This bill creates a new separate nonlapsible trust fund designated as the
17	17	medicinal psilocybin treatment fund and establishes a pilot program to study the
18	18	effects of medicinal psilocybin treatment on patients with post-traumatic stress
19	19	syndrome (PTSD).
20	20	The medicinal psilocybin treatment pilot program created by this bill must be
21	21	established by the Board of Regents of the University of Wisconsin System at the
22	22	University of Wisconsin-Madison in collaboration with that institution's
23	23	Transdisciplinary Center for Research in Psychoactive Substances and its School of
24	24	Pharmacy. The individuals eligible to participate in the pilot program must be
25	25	veterans who are 21 years of age or older and who suffer from treatment-resistant
26	26	PTSD. Individuals who are law enforcement officers are not eligible to participate
27	27	in the pilot program study. The psilocybin therapy provided by the pilot program
28	28	must be provided through pathways approved by the federal Food and Drug
29	29	Administration, and the research accomplished in the pilot program may be
30	30	accomplished in conjunction with other medications approved by the federal Food
31	31	1
32	32	2
33	33	3
34	34	4
35	35	5 - 2 -2023 - 2024 Legislature LRB-5129/1
36	36	JAM:cjs&emw
37	37	SENATE BILL 727
38	38	and Drug Administration. The board must ensure that no health information
39	39	disclosed in the course of conducting the program contains personally identifiable
40	40	information. The researchers conducting the program must create reports for the
41	41	governor and the appropriate standing committees of the legislature regarding
42	42	progress of the pilot program and the studies conducted as part of the program.
43	43	The medicinal psilocybin treatment fund created in this bill consists of
44	44	donations, gifts, grants, bequests, moneys transferred from the general fund, and all
45	45	earnings and other investment income of the fund. This trust fund is managed by
46	46	the State of Wisconsin Investment Board. Moneys in the fund may be expended for
47	47	the purpose for which any donation, gift, grant, or bequest is made and for the
48	48	administration of the pilot program.
49	49	For further information see the state fiscal estimate, which will be printed as
50	50	an appendix to this bill.
51	51	The people of the state of Wisconsin, represented in senate and assembly, do
52	52	enact as follows:
53	53	SECTION 1. 20.005 (3) (schedule) of the statutes: at the appropriate place, insert
54	54	the following amounts for the purposes indicated:
55	55	2023-24 2024-25
56	56	20.285 University of Wisconsin System
57	57	(1) UNIVERSITY EDUCATION, RESEARCH AND PUBLIC
58	58	SERVICE
59	59	(qh)Medicinal psilocybin treatment
60	60	pilot program SEG A 100,000 -0-
61	61	SECTION 2. 20.285 (1) (qh) of the statutes is created to read:
62	62	20.285 (1) (qh) Medicinal psilocybin treatment pilot program. From the
63	63	medicinal psilocybin treatment fund, the amounts in the schedule for the operations
64	64	of the medicinal psilocybin treatment pilot program under s. 36.25 (16).
65	65	SECTION 3. 20.285 (1) (qi) of the statutes is created to read:
66	66	1
67	67	2
68	68	3
69	69	4
70	70	5
71	71	6
72	72	7
73	73	8
74	74	9
75	75	10
76	76	11
77	77	12 - 3 -2023 - 2024 Legislature
78	78	LRB-5129/1
79	79	JAM:cjs&emw
80	80	SECTION 3
81	81	SENATE BILL 727
82	82	20.285 (1) (qi) Medicinal psilocybin treatment pilot program donations, gifts,
83	83	grants, and bequests. From the medicinal psilocybin treatment fund, all moneys
84	84	received from donations, gifts, grants, and bequests to the medicinal psilocybin
85	85	treatment pilot program under s. 36.25 (16) to carry out the purpose for which
86	86	received.
87	87	SECTION 4. 25.14 (1) (a) 14m. of the statutes is created to read:
88	88	25.14 (1) (a) 14m. The medicinal psilocybin treatment fund.
89	89	SECTION 5. 25.17 (1) (jw) of the statutes is created to read:
90	90	25.17 (1) (jw) The medicinal psilocybin treatment fund (s. 25.51).
91	91	SECTION 6. 25.51 of the statutes is created to read:
92	92	25.51 Medicinal psilocybin treatment fund. There is established a
93	93	separate nonlapsible trust fund designated as the medicinal psilocybin treatment
94	94	fund. The fund shall consist of all of the following:
95	95	(1) Donations, gifts, grants, and bequests deposited into the fund under s. 36.25
96	96	(16) (b).
97	97	(2) Moneys transferred under s. 36.25 (16) (c).
98	98	(3) All earnings and other investment income of the fund.
99	99	SECTION 7. 36.25 (16) of the statutes is created to read:
100	100	36.25 (16) MEDICINAL PSILOCYBIN TREATMENT PILOT PROGRAM. (a) 1. The board
101	101	shall establish at the University of Wisconsin-Madison in collaboration with that
102	102	institution's transdisciplinary center for research in psychoactive substances and its
103	103	school of pharmacy a pilot program to study the effects of medicinal psilocybin
104	104	treatment on patients with post-traumatic stress syndrome and related
105	105	comorbidities.
106	106	1
107	107	2
108	108	3
109	109	4
110	110	5
111	111	6
112	112	7
113	113	8
114	114	9
115	115	10
116	116	11
117	117	12
118	118	13
119	119	14
120	120	15
121	121	16
122	122	17
123	123	18
124	124	19
125	125	20
126	126	21
127	127	22
128	128	23
129	129	24 - 4 -2023 - 2024 Legislature LRB-5129/1
130	130	JAM:cjs&emw
131	131	SECTION 7 SENATE BILL 727
132	132	2. The individuals eligible for the pilot program under subd. 1. shall be
133	133	veterans, as defined by the board, who are 21 years of age or older and who suffer
134	134	from treatment-resistant post-traumatic stress syndrome. An individual who is a
135	135	law enforcement officer, as defined in s. 165.85 (2) (c), or a tribal law enforcement
136	136	officer, as defined in s. 165.85 (2) (g), may not participate in the pilot program under
137	137	subd. 1.
138	138	3. The pilot program under subd. 1. shall provide psilocybin therapy through
139	139	pathways approved by the federal food and drug administration.
140	140	4. The pilot program under subd. 1. may accomplish its research in conjunction
141	141	with other medications approved by the federal food and drug administration.
142	142	5. The board shall ensure that no health information disclosed by the pilot
143	143	program under subd. 1. contains personally identifiable information, as defined
144	144	under s. 19.62 (5).
145	145	6. On the first day of the 6th month beginning after the effective date of this
146	146	subdivision .... [LRB inserts date], and every 6 months thereafter while the pilot
147	147	program under subd. 1. continues, the board shall submit to the governor and to the
148	148	appropriate standing committees of the legislature under s. 13.172 (3) a report
149	149	prepared by the researchers conducting the pilot program that details the progress
150	150	of the pilot program's study.
151	151	7. Within 6 months of the completion of a study in the pilot program under subd.
152	152	1., the board shall submit to the governor and to the appropriate standing
153	153	committees of the legislature under s. 13.172 (3) a report prepared by the researchers
154	154	conducting the study detailing the results of the study and any recommendations for
155	155	legislation based on the study results.
156	156	1
157	157	2
158	158	3
159	159	4
160	160	5
161	161	6
162	162	7
163	163	8
164	164	9
165	165	10
166	166	11
167	167	12
168	168	13
169	169	14
170	170	15
171	171	16
172	172	17
173	173	18
174	174	19
175	175	20
176	176	21
177	177	22
178	178	23
179	179	24 - 5 -2023 - 2024 Legislature
180	180	LRB-5129/1
181	181	JAM:cjs&emw
182	182	SECTION 7
183	183	SENATE BILL 727
184	184	8. Within 6 months of the completion of the pilot program under subd. 1., the
185	185	board shall submit to the governor and to the appropriate standing committees of the
186	186	legislature under s. 13.172 (3) a report prepared by the researchers conducting the
187	187	pilot program detailing the final results of the pilot program and any
188	188	recommendations for legislation based on the pilot program's results.
189	189	(b) The board, the University of Wisconsin-Madison, the University of
190	190	Wisconsin-Madison's school of pharmacy and the program under par. (a) 1. may
191	191	receive donations, gifts, grants, and bequests to the program and use any donation,
192	192	gift, grant, or bequest for the purpose for which it is made. The board shall deposit
193	193	the amount of any donation, gift, grant, or bequest into the medicinal psilocybin
194	194	treatment fund.
195	195	(c) The secretary of administration shall annually transfer from the general
196	196	fund to the medicinal psilocybin treatment fund the amount in the schedule under
197	197	20.285 (1) (qh) for the applicable fiscal year.
198	198	(END)
199	199	1
200	200	2
201	201	3
202	202	4
203	203	5
204	204	6
205	205	7
206	206	8
207	207	9
208	208	10
209	209	11
210	210	12
211	211	13
212	212	14
213	213	15